# INREAL - Nintedanib for Changes in Dyspnea and Cough in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease (ILD) With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation

> **NCT04702893** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 108 (actual)

## Conditions studied

- Lung Diseases, Interstitial

## Interventions

- **DRUG:** Nintedanib

## Key facts

- **NCT ID:** NCT04702893
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-28
- **Primary completion:** 2024-04-09
- **Final completion:** 2024-04-09
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2025-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04702893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04702893, "INREAL - Nintedanib for Changes in Dyspnea and Cough in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease (ILD) With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04702893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*